CL2009000956A1 -
Sustained release pharmaceutical composition comprising a particulate nmda receptor antagonist and a triblock copolymer, with an osmolarity between 100-500 mosm / l; and its use to treat an otic disorder, such as meniere's disease or hearing loss.
- Google Patents
Sustained release pharmaceutical composition comprising a particulate nmda receptor antagonist and a triblock copolymer, with an osmolarity between 100-500 mosm / l; and its use to treat an otic disorder, such as meniere's disease or hearing loss.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Otonomy IncfiledCriticalUniv California
Priority to ARP090102772priorityCriticalpatent/AR072828A1/en
Publication of CL2009000956A1publicationCriticalpatent/CL2009000956A1/en
Composición farmacéutica que comprende un agente inmunomodulador, un copolímero de tribloque, agua estéril y un amortiguador, con una osmolaridad entre 250-320 mosm/l, menos de 50cfu de agentes microbiológicos por gramo, y menos de 0,5 unidades de endotóxina por ml; y su uso para tratar un desorden otico, como la enfermedad de Maniere, pérdida auditiva.Pharmaceutical composition comprising an immunomodulatory agent, a triblock copolymer, sterile water and a buffer, with an osmolarity between 250-320 mosm / l, less than 50cfu of microbiological agents per gram, and less than 0.5 endotoxin units per ml ; and its use to treat an otic disorder, such as Maniere's disease, hearing loss.
CL2009000956A2008-04-212009-04-21
Sustained release pharmaceutical composition comprising a particulate nmda receptor antagonist and a triblock copolymer, with an osmolarity between 100-500 mosm / l; and its use to treat an otic disorder, such as meniere's disease or hearing loss.
CL2009000956A1
(en)
Sustained release pharmaceutical composition comprising a particulate nmda receptor antagonist and a triblock copolymer, with an osmolarity between 100-500 mosm / l; and its use to treat an otic disorder, such as meniere's disease or hearing loss.
Intravaginal delivery system with a compartment comprising drospirenone and a compartment, the same or different, with an estrogen, each compartment comprises a core and a membrane that covers it consisting of a polymer composition containing an elastomer based on polydimethylsiloxane with polyoxide groups alkylene.
Use of bacillus subtilis qst713 nrrl b-21661 to formulate a probiotic composition for an animal; and probiotic composition of bacillus subtilis qst713 nrrl b-21661.
Compounds derived from imidazopyridinones, tlr7 agonist; preparation procedure; intermediate compounds; pharmaceutical composition comprising them; and use in viral, bacterial and fungal infections.
Interference RNA Agent (IARN); pharmaceutical composition comprising it; and its use to treat pathological processes mediated at least in part by the expression of the epithelial sodium channel alpha (alpha-enac)
A topical ophthalmic composition for the treatment and / or prophylaxis of an infection caused by a microorganism or a disorder of at least one eye tissue, comprising a) 0.01 to 10% povidone iodine and b) a steroid selected from acetate of prednisolone, loteprednol ethabonate, difluprednate, among others, or bromfenac.
Use of benzene-derived sglt-2 inhibitor compounds substituted by glucopyranosyl to prevent, slow progression, delay or treat a metabolic disorder in a patient with a neuroleptic agent; use of the combination of the sglt2 inhibitor with a neuroleptic; and pharmaceutical composition of the combination.
Ophthalmic composition comprising between 0.16 and 0.19% w / v of a galactomannan, about 0.7% w / v of a borate, cis-diol and less than 5 ppm concentration of divalent cations; and its use to lubricate the eye.
Use of a composition comprising at least one glucan, at least one fucan, or at least one glucan and at least one fucan, to improve or maintain the gastrointestinal health or function of a progeny of a maternal animal by administration to the maternal animal and the composition used.